Table 3. Diagnostic performance of LSM for each histopathological fibrosis stage as determined by biopsy interpretation.

Patient group	Liver biopsy fibrosis stages	AUROC (95% confidence interval)	LSM cut-off, kPa	Sensitivity	Specificity	PPV	NPV
All patients, Youden’s index (n=109)	Stage 0 vs. 1–4	0.74 (0.64–0.83)	11.95	0.53	0.91	0.93	0.48
	Stage 0–1 vs. 2–4	0.80 (0.72–0.89)	12.3	0.67	0.88	0.83	0.75
	Stage 0–2 vs. 3–4	0.87 (0.80–0.93)	10.75	0.94	0.69	0.56	0.96
	Stage 0–3 vs. 4	0.90 (0.83–0.98)	20.45	0.83	0.85	0.40	0.98
All patients, sensitivity=0.90 (n=109)	Stage 0 vs. 1–4		5.55	0.90	0.34	0.74	0.62
	Stage 0–1 vs. 2–4		6.85	0.90	0.47	0.60	0.84
	Stage 0–2 vs. 3–4		11.05	0.90	0.72	0.57	0.95
	Stage 0–3 vs. 4		13.25	0.90	0.71	0.28	0.98
All patients, specificity=0.90 (n=109)	Stage 0 vs. 1–4		11.95	0.53	0.90	0.92	0.47
	Stage 0–1 vs. 2–4		14.05	0.64	0.90	0.85	0.74
	Stage 0–2 vs. 3–4		23.35	0.41	0.90	0.63	0.78
	Stage 0–3 vs. 4		25.40	0.67	0.90	0.45	0.96

AUROC, area under the receiver operating characteristics; LSM, liver stiffness measurement; NPV, negative predictive value; PPV, positive predictive value.